CXCL12 and hematologic disorder: Ulocuplumab, a completely human IgG4 anti-CXCR4 antibody, able to inhibit CXCL12 binding to its receptor, has shown promise in preclinical research and early-stage clinical trials for various hematological malignancies [43].